Press Releases

Date Title and Summary View
August 16, 2016 Eleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031 View HTML
August 12, 2016 Eleven Biotherapeutics Reports Second Quarter 2016 Financial Results and Provides Strategic Update View HTML
July 7, 2016 Eleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031 View HTML
June 13, 2016 Eleven Biotherapeutics Announces Signing of Exclusive License Agreement View HTML
June 13, 2016 Eleven Biotherapeutics Announces Investigational New Drug Application Submission to Initiate Clinical Trials of EBI-031 for Ocular Diseases View HTML
May 5, 2016 Eleven Biotherapeutics Reports First Quarter 2016 Financial Results View HTML
April 29, 2016 Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting View HTML
March 24, 2016 Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Strategic Update View HTML
January 26, 2016 Albumedix and Eleven Biotherapeutics Announce Albumin Variant Technology Agreement
Albumedix strengthens its leading position in albumin-based drug delivery through acquisition of Eleven's Supermin® albumin technology
View HTML
January 15, 2016 Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis View HTML